Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease
Patent 4035507 Issued on July 12, 1977. Estimated Expiration Date: 
July 12, 1994. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
July 12, 1994. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.InventorsAssigneeApplicationNo. 05/708285 filed on 07/23/1976US Classes:514/533, Compound contains two or more C(=O)O groups indirectly bonded together by only conalent bonds514/538, Nitrogen bonded to carbon in Z moiety514/539, Plural separated benzene rings in Z moiety514/540, Nitrogen in Y moiety514/542, Z radical contains two or more nitrogen atoms at least one of which forms a C(=X)N group (X is chalcogen)514/561, Nitrogen other than as nitro or nitroso nonionically bonded514/563, RC(=O)N containing (i.e., carboxamide) (R is C or H)514/564, Plural nitrogens nonionically bonded514/566, Polycarboxylic acid514/567Benzene ring nonionically bondedExaminersPrimary: Friedman, Stanley J.Attorney, Agent or FirmAbstractThere is provided, novel, transient pro-drug forms of L-DOPA (3,4-dihydroxy-L-phenylalanine), having the formula: ##STR1## wherein R represents a hydrogen atom, an acyl group, ##STR2## group, a -CO-pyridyl group, and a -CO-R3 group, wherein R3 represents the residue of any N,N-C1 -C2 dialkylamino acid or a C4 -C6 cycloalkylamino acid (e.g., ##STR3## wherein R1 represents a member selected from the group consisting of a hydroxyl group and a --OM group, wherein M is an alkali metal (Na, K, etc.) or an ammonium ion; and wherein R2 represents a member selected from the group consisting of a ##STR4## group, a -CO-pyridyl group, and a --CO-R3 group, wherein R3 represents the residue of any N,N-(C1 -C2)--dialkylamino acid or a C4 -C6 -cycloalkylamino acid (e.g., ##STR5## wherein R represents an acyl group; wherein R2 represents a hydrogen atom; and wherein R1 represents a --NHCH(R4)COOR5 group, wherein R4 represents the residue of any naturally occurring amino acid, and wherein R5 represents a member selected from the group consisting of a hydrogen atom, a C1 -C5 alkyl group (e.g., methyl, ethyl, propyl, butyl, pentyl), and a C1 -C5 alkylaryl group (e.g., --CH2 -C6 H5, --CH2 -CH2 --C6 H5, etc.), and the HX salts thereof, wherein X is a conventional pharmaceutically acceptable acid addition salt anion (e.g., chloride, bromide, perchlorate, methanesulfonate, succinate, etc.); ##STR6## wherein R represents an acyl group; wherein R1 represents a member selected from the group consisting of a hydroxyl group, a --OCH3 group, a --OC2 H5 group, a --OC3 H7 group, a --OC4 H9 group, and a -OCH2 -C6 H5 group; and wherein R2 represents an NH2 CH(R6)CO-- group, wherein R6 represents the residue of any naturally occurring amino acid, and the HX salts thereof, wherein X is defined as above; ##STR7## wherein R represents a member selected from the group consisting of an acyl group; wherein R1 represents a member selected from the group consisting of a hydroxyl group, a --OCH3 group, a --OC2 H5 group, a --OC3 H7 group, a --OC4 H9 group, and a --OCH2 -C6 H5 group; and wherein R2 represents an NH2 -CH(R7)--CO-- group, wherein R7 represents the residue of a 3,4-L-diacylphenylalanine group having the formula: ##STR8## wherein R is defined as above, and the HX salts thereof, wherein X is as defined above; and ##STR9## wherein n represents an integer of from 2 to 50 with respect to formula (V-A), and wherein n represents an integer of from 1 to 50 with respect to formula (V-B).These compounds are all useful in the treatment of Parkinson's Disease. | |
